Intuitive Surgical (ISRG) was Downgraded by Northland Capital to ” Under Perform” and the brokerage firm has set the Price Target at $600. Earlier the firm had a rating of “Market Perform ” on the company shares. Northland Capital advised their investors in a research report released on Jul 21, 2016.
Many Wall Street Analysts have commented on Intuitive Surgical. Company shares were Reiterated by Wedbush on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 755 from a previous price target of $715 .Company shares were Reiterated by Canaccord Genuity on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 750 from a previous price target of $700 .Company shares were Reiterated by Stifel on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 800 from a previous price target of $700 .
On the company’s financial health, Intuitive Surgical reported $5.62 EPS for the quarter, beating the analyst consensus estimate by $ 0.63 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $4.99. The company had revenue of $670.10 million for the quarter, compared to analysts expectations of $642.46 million. The company’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.57 EPS.
Intuitive Surgical opened for trading at $712.08 and hit $720.005 on the upside on Wednesday, eventually ending the session at $703.05, with a gain of 4.64% or 31.15 points. The heightened volatility saw the trading volume jump to 11,60,040 shares. Company has a market cap of $26,758 M.
In a different news, on Jun 3, 2016, Salvatore Brogna (EVP – Product Operations) sold 600 shares at $630.96 per share price. According to the SEC, on May 18, 2016, Curet Myriam (SVP & Chief Medical Officer) sold 530 shares at $629.36 per share price. On May 18, 2016, Lonnie M Smith (director) sold 2,000 shares at $627.23 per share price, according to the Form-4 filing with the securities and exchange commission.
Intuitive Surgical Inc. designs manufactures and markets da Vinci Surgical Systems and related instruments and accessories. The Company’s da Vinci Surgical System consists of a surgeon’s console a patient-side cart and vision system. The da Vinci Surgical System provides its operating surgeons with control range of motion tissue manipulation and three-dimensional (3-D) high-definition (HD) vision. It allows surgeons to work through the small ports enabled by minimally invasive surgery (MIS) procedures. Its da Vinci Surgery utilizes computational robotic and imaging technologies. The Company has four generations of da Vinci Surgical System: the da Vinci Xi Surgical System the da Vinci Si Surgical System the da Vinci S Surgical System and the standard da Vinci Surgical System. The Company focuses on five surgical specialties: urologic surgery gynecologic surgery general surgery cardiothoracic surgery and head and neck surgery.